RNS Number:6892D
Celsis International PLC
04 October 2004

                             CAPITAL REORGANISATION

                            Celsis International plc

                       Reduction of Share Premium Account



4 October 2004: Celsis International plc announces that it is proposing to
reduce its share premium account by $10,000,000 in order to increase
distributable reserves for the purpose, among others, of paying dividends to
shareholders.  The reduction will require the approval of the Company's
shareholders at an extraordinary general meeting convened for 9.00 am on 28
October 2004 at Eversheds LLP, Senator House, 85 Queen Victoria Street, London
EC4V 1JL and subsequent confirmation by the Companies Court.  The petition to
approve the reduction of the share premium account is expected to be heard on 17
November 2004 and the reduction is expected to be effective on 19 November 2004.



Copies of the circular issued by the Company in connection the reduction of
share premium account have been submitted to the UK Listing Authority, and are
available for inspection at the UK Listing Authority's Document Viewing
Facility, which is situated at: Financial Services Authority, 25 The North
Colonnade, Canary Wharf, London, E14 5HS (Tel: 020 7676 1000).


Enquiries:

Celsis International plc                                     Tel: 01638 600 151
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

Financial Dynamics                                           Tel: 020 7831 3113
David Yates
Lucy Briggs



Notes to editors

Celsis International plc



Based in Newmarket, UK, Celsis International Plc is a microbial detection and
analytical services company operating through two divisions, the Product Group
and the Laboratory Group.



Using its proprietary enzyme technology, the Product Group is the world leader
in the provision of diagnostic systems for the rapid detection of microbial
contamination.  It works in close collaboration with many of the world's leading
pharmaceutical, personal care and beverage companies, ensuring the safety and
quality of products bound for consumers.  The Laboratory Group provides
outsourced analytical testing services to pharmaceutical companies to ensure the
stability and chemical composition of their products.



In addition to ensuring product quality and safety for consumers, both divisions
have the capacity to deliver substantial cost savings to Celsis' customers.  By
reducing the time it takes to test and release raw materials and finished goods
to the market place, Celsis' products facilitate increased manufacturing
productivity and improved supply chain management.



Celsis International plc is listed on the London Stock Exchange (CEL.L).
Further information can be found on the Company's website at www.celsis.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCQZLFBZBBZFBD
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.